Special Issue

Emerging Trends in Brain Stimulation

Message from the Guest Editors

This is an exciting time in the field of brain stimulation. Transcranial magnetic stimulation (TMS) and its variants rapidly expand clinical indications and efficacy, while novel and portable transcranial electric stimulation (tES) devices are being increasingly used and researched in clinical trials. The mechanisms of action of these techniques are progressively being unveiled, which allows researchers to use multimodal methods to provide a better prediction of response. In addition, magnetic seizure therapy is being evaluated as an alternative intervention for electroconvulsive therapy, reducing cognitive side effects while maintaining clinical efficacy. This Special Issue invites researchers in the field to submit their recent findings that fall under the scope of these emerging trends. We welcome both original and review work, as well as manuscripts describing clinical findings, mechanisms of action, translational research, modelling, bioengineering, and animal studies.

Guest Editors

Dr. Andre Russowsky Brunoni

Dr. Paul E. Croarkin

Dr. Lais Boralli Razza

Deadline for manuscript submissions

closed (30 April 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/148180

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).